Nov 14 2024 10 mins
In this edition, single-fraction SBRT outcomes for central lung tumors, adjuvant durvalumab extends survival in limited-stage small cell lung cancer and more.
Read the full coverage here:
Single-fraction SBRT confers ‘surprisingly excellent’ outcomes for central lung tumors
Adjuvant durvalumab extends survival in limited-stage small cell lung cancer
Depression among people with head and neck cancers likely underreported, undertreated
FDA approves tumor treating fields as part of combination therapy for advanced lung cancer
First-line maintenance regimen improves OS, PFS in extensive-stage small cell lung cancer
References:
Cheng Y, et al. Abstract LBA81. Presented at: European Society for Medical Oncology Congress; Sept. 13-17, 2024; Barcelona, Spain.
Malik NK, et al. Abstract 285. Presented at: ASTRO Annual Meeting; Sept. 29-Oct. 2, 2024; Washington, D.C.
Martinez MC, et al. JAMA Otolaryngol Head Neck Surg. 2024;doi:10.1001/jamaoto.2024.3233.